Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in ...

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

Tear film stability, tear production, ocular surface health, and symptoms were all significantly improved with the use of ...

According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for ...